CV Sciences (CVSI) Cash from Investing Activities (2013 - 2026)
CV Sciences (CVSI) reported Cash from Investing Activities of -$3000.0 for Q1 2026, up 92.5% on a YoY basis from -$1558.4 in Q1 2025, and up 66.67% sequentially from -$9000.0 in Q4 2025.
CV Sciences (CVSI) Cash from Investing Activities (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 13 years of Cash from Investing Activities data on file, last reported at -$3000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 92.5% year-over-year to -$3000.0; the trailing twelve-month figure through Mar 2026 stood at -$72000.0 (down 5.88% YoY), and the FY2025 full-year result was -$109000.0, down 289.29% from the prior year.
- Cash from Investing Activities rose to -$3000.0 in Q1 2026, from -$9000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $34000.0 in Q3 2024 to a low of -$156000.0 in Q4 2023.
- A 4-year average of -$32888.9 and a median of -$22000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities slumped 132.35% in 2025 and jumped 92.5% in 2026, its largest moves.
- Tracing CVSI's Cash from Investing Activities over 4 years: stood at -$156000.0 in 2023, then jumped by 85.9% to -$22000.0 in 2024, then surged by 59.09% to -$9000.0 in 2025, then soared by 66.67% to -$3000.0 in 2026.
- Business Quant data shows CVSI's Cash from Investing Activities at -$3000.0 in Q1 2026, -$9000.0 in Q4 2025, and -$11000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -40,000.00 |
| Mar 31, 2025 | -40,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Jun 30, 2024 | -40,000.00 |
| Jun 30, 2024 | -40,000.00 |
| Dec 31, 2023 | -156,000.00 |
| Dec 31, 2023 | -156,000.00 |
| Mar 31, 2021 | -35,000.00 |
| Mar 31, 2021 | -35,000.00 |